ClinicalTrials.Veeva

Menu

Fibroids in Women of Reproductive Age and Women Pregnancy

T

Trieu, Nguyen Thi, M.D.

Status and phase

Completed
Phase 4

Conditions

Fibroids

Treatments

Drug: Dydrogesterone M ( case 1 )
Drug: Dydrogesterone M ( case 2 )

Study type

Interventional

Identifiers

NCT02620345
Dydrogesterone Multivitamin

Details and patient eligibility

About

Dydrogesterone Multivitamin Nature treatment of fibroids in women of reproductive age and women pregnancy to lost the size fibroids.

Full description

Uterine fibroids are a very common finding in women of reproductive age. But may fibroids grow in the first trimester pregnancy.

Clinically has shown that:

Uterine fibroids are associated with an Heavy or prolonged menstrual periods. Abnormal bleeding between menstrual periods.

Uterine fibroids are associated with an increased rate of spontaneous miscarriage, preterm labor, placenta abruption, malpresentation, labor dystocia, cesarean delivery, and postpartum hemorrhage, pain is the most common complication of fibroids during pregnancy. Can usually be controlled by conservative treatment on Dydrogesterone Multivitamin nature.

Enrollment

22 patients

Sex

Female

Ages

18 to 35 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Procedure to treatment of fibroids in pregnancy and in women desiring future fertility.

Exclusion criteria

  • Whether or not you are having symptoms from the fibroids
  • If you might want to become pregnant in the future
  • The size of the fibroids
  • The location of the fibroids
  • Your age and you might be

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

22 participants in 2 patient groups

Dydrogesterone M/ Women Pregnancy
Experimental group
Description:
* Reducing the size of fibroids with medication * Drug: Dydrogesterone M 15mg/Fibroids/Women Pregnancy * Dosage: * 1tablet/24 hours/day/ (when seeing fibroids to 4 weeks after postpartum). Dydrogesterone 15mg/day Beta Carotene 4000 IU/day Ascorbic Acid 100 mg/day Cholecalciferol 400 IU/day Dl-Alpha Tocopheryl Acetate 11IU Thiamin Mononitrate 1.5 mg/day Riboflavin 1.7 mg/day Niacinamide 18 mg/day Pyridoxine Hydrochloride 2.6 mg/day Folic Acid 400 mcg/day Cyanocobalamin 4mcg/day Calcium Carbonate 150 mg/day Ferrous Fumarate 27 mg/day Zinc Oxide 25 mg/day * The lost in size of fibroids throughout pregnancy after 48 weeks.
Treatment:
Drug: Dydrogesterone M ( case 1 )
Dydrogesterone M/ Reproductive Age
Experimental group
Description:
* Reducing the size of fibroids with medication * Drug: Dydrogesterone M 15mg/Fibroids/Reproductive Age * Dosage: * 1tablet/24 hours/day/24 weeks ( from discovered fibroids through 24 weeks). Dydrogesterone 15mg/day Beta Carotene 4000 IU/day Ascorbic Acid 100 mg/day Cholecalciferol 400 IU/day Dl-Alpha Tocopheryl Acetate 11IU Thiamin Mononitrate 1.5 mg/day Riboflavin 1.7 mg/day Niacinamide 18 mg/day Pyridoxine Hydrochloride 2.6 mg/day Folic Acid 400 mcg/day Cyanocobalamin 4mcg/day Calcium Carbonate 150 mg/day Ferrous Fumarate 27 mg/day Zinc Oxide 25 mg/day * The lost in size of fibroids after 24 weeks.
Treatment:
Drug: Dydrogesterone M ( case 2 )

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems